occurs in has disease treated with drug INTERFERON ALFA-2A VENLAFAXINE VINORELBINE ROPINIROLE LEUPROLIDE ACETATE NORFLOXACIN DILTIAZEM DOXORUBICIN FLUOXETINE TOLMETIN ALDESLEUKIN FLUDARABINE PHOSPHATE SOTALOL PAROXETINE ANASTROZOLE BICALUTAMIDE RITONAVIR DOCETAXEL ZOLMITRIPTAN CAPECITABINE RITUXIMAB TRASTUZUMAB ZALEPLON BEXAROTENE ZIPRASIDONE TENOFOVIR ELETRIPTAN BORTEZOMIB EMTRICITABINE NILOTINIB CABAZITAXEL ERIBULIN female breast cancer mature T-cell and NK-cell lymphoma non-Hodgkin lymphoma heart conduction disease prostate cancer prostate carcinoma chronic lymphocytic leukemia leiomyoma acute cystitis lung cancer generalized anxiety disorder Parkinson's disease prostatitis major depressive disorder breast cancer hepatitis C post-traumatic stress disorder colon cancer ovarian cancer non-small cell lung carcinoma renal cell carcinoma human immunodeficiency virus infectious disease sleep disorder schizophrenia panic disorder migraine rheumatoid arthritis chronic myeloid leukemia Kaposi's sarcoma intermediate coronary syndrome multiple myeloma Elderly Child Adult asthenia AE 10003549 HPO: HP_0001324 SIDER: C0004093 YH a muscle adverse event which has an outcome of asthenia, which is a medical term denoting symptoms of physical weakness and loss of strength. muscle AE